Will IBRX report cash and marketable securities below $150 million as of September 30, 2026?

Cash at March 31, 2026 is $380.9M. To cross below $150M by September 30, 2026 requires ~$230M net outflow in 6 months — approximately 3x the Q1 organic burn rate. This would require no further financing AND accelerated spend, both contrary to observed patterns. Low probability.

The company demonstrated willingness to raise opportunistically (Oberland RIPA tranche + likely ATM in Q1). Between revenue of ~$90-100M for Q2+Q3 combined and additional financing capacity, staying above $150M is the overwhelming base case. Down-side tail from a clinical setback or withdrawn financing access.

Management has shown no signal of reducing spend; rather, commercial expansion is accelerating. Operating burn may increase to $80-90M/quarter on launch investments. Even at this higher burn rate, $380.9M - 2x$85M = $210.9M without any financing or revenue offset. Clearing $150M is very probable.

Runway extended materially. For Q3 cash <$150M: requires $230M net decline over ~6 months. Even aggressive spending + zero financing would take ~3 quarters to hit, not 2. Low probability.

Historical pattern: cash build → maintain for 2-3 quarters before next raise. The Q1 build was large enough to preclude a second raise in Q2 or Q3 under most scenarios. Cash at Q3 likely in $220-280M range, well above $150M.

The question was designed around a 9.5-month runway assumption that no longer applies. With new runway of 15-20+ months, crossing below $150M by end Q3 is a tail scenario requiring multiple adverse events (clinical setback + financing closure + spending acceleration).

Cash jumped to $380.9M. Very hard to drop below $150M in 2 quarters. Low probability.

Structural headroom plus active financing means very low probability of crossing threshold this year.

Baseline 0.55 was anchored on $242.8M starting point. With $380.9M plus demonstrated financing access, recalibrate to low teens.